[BIO USA] GI Innovation Highlights Pulmonary Arterial Hypertension Drug Candidate

GI Innovation announced on the 25th (local time) that it was selected to present at the 'Company Presentation' session, an official program of BIO International Convention 2026 (BIO USA), the world's largest bio event currently underway in San Diego, USA.

Dr. Lee Farrand, Executive Director of Business Development at GI Innovation, is presenting at the 'Company Presentation' session, an official program of the BIO International Convention 2026, the world's largest bio event currently taking place in San Diego, USA, on the 25th (local time). GI Innovation

During this presentation, GI Innovation focused on introducing the clinical development achievements of GI-101A and GI-102, which are being developed in clinical collaboration with global pharmaceutical companies such as Merck (MSD) and Johnson & Johnson. The company also highlighted GI-214, a next-generation pulmonary arterial hypertension (PAH) drug candidate.

GI-214 is a next-generation PAH drug candidate that GI Innovation is developing as part of its efforts to expand its pipeline from the immuno-oncology sector into the cardiovascular and rare disease areas.

Pulmonary arterial hypertension is a rare and intractable disease in which pulmonary blood vessels abnormally narrow, causing increased pulmonary arterial pressure and putting a burden on the heart. There is a high unmet medical need for new treatments in this field. The global PAH therapeutics market is currently estimated at around USD 8 billion (approximately KRW 11 trillion) and is expected to grow to over USD 13 billion (approximately KRW 18 trillion) by 2033.

At this BIO USA event, in addition to the official 'Company Presentation', the company held multiple business development (BD) meetings with global pharmaceutical companies to discuss technology transfer and global collaboration, focusing on its next-generation immuno-oncology drugs GI-101A, GI-102, GI-108, and the PAH candidate GI-214. In particular, global pharmaceutical companies showed significant interest in GI-214, which is still in the preclinical pipeline, and active discussions were held on possible new partnerships.

Myeongho Jang, CEO of GI Innovation, who is attending the event, stated, "Based on our diverse pipeline and differentiated technologies, we are pursuing various business development strategies, including in-house development, technology transfer, and clinical collaboration," adding, "We will do our best to deliver tangible results."

This content was produced with the assistance of AI translation services.